文献速递生殖医学母胎医学

9岁经胚胎植入前遗传学筛查出生儿童的发育结局:一项随机试验的随访

Developmental outcome of 9-year-old children born after PGS: follow-up of a randomized trial.
PubMed 文献 · Hum Reprod · 2018-01-01

该前瞻性、评估者盲法、多中心随访研究评估了9岁经第3天卵裂期胚胎植入前遗传学筛查(PGS)出生的体外受精(IVF)子代的神经发育。结果显示PGS组与对照组的神经发育最优评分、智力商、行为、血压及人体测量学均无显著差异,但两组不良神经结局患病率均较高。

要点

  • 9岁时PGS组与对照组的神经发育最优评分无显著差异。
  • 两组不良神经结局患病率无显著差异,但复杂型轻微神经功能障碍患病率均较高。
  • 两组智力商、行为、血压及人体测量学均无显著差异。

核心结论

  • 第3天卵裂期胚胎PGS对9岁IVF子代的神经发育、认知、行为、血压及人体测量学未见不良影响证据。
  • 但两组IVF子代均表现出较高比例的临床相关轻微神经功能障碍,且可能面临不利心血管结局风险。

研究设计与样本

  • 前瞻性、评估者盲法、多中心随访研究,随访9岁IVF儿童,随访检查于2014年3月至2016年5月进行。
  • 共408名女性随机分配至IVF联合第3天卵裂期PGS组或不联合PGS的对照组,PGS组持续妊娠52例、对照组74例,活产分别为59名和85名。
  • 9岁时参与研究的儿童为PGS组43名、对照组56名。

主要发现

  • 神经发育最优评分均值(95%CI):PGS组51.5(49.3;53.7)vs 对照组53.1(50.5;55.7),无显著差异。
  • 不良神经结局患病率:PGS组17/43(40%)vs 对照组19/56(34%),无显著差异,但两组复杂型轻微神经功能障碍患病率均较高。
  • 智力商:PGS组114(108;120)vs 对照组117(109;125),无显著差异。
  • 行为、血压及人体测量学两组无差异,两组平均血压均高于第60百分位。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究的效能分析基于检测PGS后持续妊娠率增加所需的女性数量,而非随访研究所需的儿童数量。
  • 本研究评估的是卵裂期(第3天胚胎活检)PGS,而当前推荐并越来越多使用囊胚期(第5天胚胎活检)PGS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does Day-3 cleavage-stage PGS affect neurodevelopment of 9-year-old IVF offspring? SUMMARY ANSWER: We did not find evidence of adverse consequences of Day-3 cleavage-stage PGS on neurodevelopment of 9-year-old IVF offspring, although children born after IVF with or without PGS often had a non-optimal neurological condition. WHAT IS KNOWN ALREADY: Knowledge on long-term sequelae for development and health of children born following PGS is lacking. This is striking as evidence accumulates that IVF itself is associated with increased risk for impaired health and development in the offspring. STUDY DESIGN SIZE, DURATION: This prospective, assessor-blinded, multicentre, follow-up study evaluated development and health of 9-year-old IVF children born to women who were randomly assigned to IVF with PGS (PGS group) or without PGS (control group). The follow-up examination at 9 years took place between March 2014 and May 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 408 women were included and randomly assigned to IVF with or without Day-3 cleavage-stage PGS. This resulted in 52 ongoing pregnancies in the PGS group and 74 in the control group. In the PGS group, 59 children were born alive; in the control group, 85 children were born alive. At the age of 9 years, 43 children born after PGS and 56 control children participated in the study. Our primary outcome was the neurological optimality score, a sensitive measure of neurological condition assessed with a standardized, age-specific test (Touwen test). Secondary outcomes were adverse neurological condition (neurologically abnormal and the complex form of minor neurological dysfunction), cognitive development (intelligence quotient and specific domains), behaviour (parental and teacher's questionnaires), blood pressure and anthropometrics. MAIN RESULTS AND THE ROLE OF CHANCE: Neurodevelopmental outcome of PGS children did not differ from that of controls; the neurological optimality scores (mean values [(95% CI]: PGS children 51.5 [49.3; 53.7], control children 53.1 [50.5; 55.7]) were not significantly different. The prevalences of adverse neurological outcome (in all but one child implying the presence of the complex form of minor neurological dysfunction) did not differ between the groups (PGS group 17/43 [40%], control group 19/56 [34%]), although the prevalence of complex minor neurological dysfunction in both groups was rather high. Also intelligence quotient scores of the two groups were not significantly different (PGS group 114 [108; 120]); control group 117 [109; 125]), and the behaviour, blood pressure and anthropometrics of both groups did not differ. Mean blood pressures of both groups were above the 60th percentile. LIMITATIONS REASONS FOR CAUTION: The power analysis of the study was not based on the number of children needed for the follow-up study, but on the number of women who were needed to detect an increase in ongoing pregnancy rates after PGS. In addition, our study evaluated embryo biopsy in the form of PGS at cleavage stage (Day-3 embryo biopsy), while currently PGS at blastocyst stage (Day-5 embryo biopsy) is recommended and increasingly being used. WIDER IMPLICATIONS OF THE FINDINGS: Our findings indicate that PGS in cleavage stage embryos is not associated with adverse effects on neurological, cognitive and behavioural development, blood pressure and anthropometrics of offspring at 9 years. This is a reassuring finding as embryo biopsy in the forms of PGS and PGD is increasingly applied. However, both groups of IVF offspring showed high prevalences of the clinically relevant form of minor neurological dysfunction, which is a point of concern for the IVF community. In addition, our study confirms findings of others that IVF offspring may be at risk of an unfavourable cardiovascular outcome. These findings are alarming and highlight the importance of research on the underlying mechanisms of unfavourable neurodevelopmental and cardiovascular outcomes in IVF offspring. STUDY FUNDING/COMPETING INTEREST(S): The randomized controlled trial was financially supported by the Organization for Health Research and Development (ZonMw), The Netherlands (Grant number 945-03-013). The follow-up was financially supported by the University Medical Center Groningen (Grant number: 754510), the Cornelia Foundation, and the graduate schools BCN and Share, Groningen, The Netherlands. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. There are no conflicts of interest. TRIAL REGISTRATION NUMBER: ISRCTN76355836.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kuiper D, Bennema A, la Bastide-van Gemert S, et al. Developmental outcome of 9-year-old children born after PGS: follow-up of a randomized trial. Hum Reprod. 2018. PMID: 29136227. doi:10.1093/humrep/dex337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。